<DOC>
	<DOCNO>NCT00566202</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness JNJ-18038683 compare escitalopram placebo patient moderate severe depression .</brief_summary>
	<brief_title>A Safety Effectiveness Study JNJ-18038683 Patients With Moderate Severe Depression</brief_title>
	<detailed_description>This study do assess safety tolerability explore effectiveness new , experimental drug treatment moderate severe depression . Approximately 225 patient depression recruit study . Patients meet study criterion need stop take depression medication currently use . They randomly assign one 3 treatment arm ; patient equal chance receive 20 mg JNJ-18038683 , 20 mg escitalopram , placebo . Placebo active drug . Escitalopram drug currently approve treat depression . This blind study , ie patient , study doctor , study sponsor know treatment patient receive patient complete study . Patients receive either escitalopram JNJ-18038683 titrate assign dose , receive 10 mg dos one week prior increase 20 mg . Patients able tolerate 20 mg JNJ-18038683 allow drop 10 mg dose time titration period . Patients take 20 mg escitalopram receive 10 mg final week taper drug . Patients receive drug blister card weekly visit contain drug upcoming week . The study doctor sponsor monitor study occurrence possible side effect . In addition screen visit , patient return weekly 9 additional study visit . After complete study , patient may resume depression medication . Medical psychiatric history , physical examination , blood pressure , heart rate , temperature , weight electrocardiogram ( ECGs ) check periodically . Blood sample take standard safety laboratory test well measurement drug blood level . Questionnaires relate depression , sleep sexual experience administer throughout study . Each day nine week , patient take orally two JNJ-18038683 tablet , active and/or placebo , two escitalopram capsule , active and/or placebo .</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Diagnosed moderate severe major depressive disorder Willing use acceptable method birth control throughout study 3 month In good general health No history current diagnosis psychiatric condition bipolar disorder , psychotic disorder , general anxiety disorder , anorexia , obsessive compulsive disorder , post traumatic stress disorder , antisocial personality disorder , mental retardation , pervasive developmental disorder , cognitive disorder No history presence drug abuse No use prescription medication herbal medication hormone replacement therapies No prior history heart disease current significant blood , lung , kidney , liver , heart , breathing , neurologic thyroid disorder No patient either pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Depression</keyword>
	<keyword>JNJ-18038683</keyword>
	<keyword>Escitalopram</keyword>
</DOC>